Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

Debra L. Barton, Charles Lawrence Loprinzi, Susan K. Quella, Jeff A Sloan, Michael H. Veeder, James R. Egner, Pat Fidler, Philip J. Stella, Debra K. Swan, Nancy L. Vaught, Paul Novotny

Research output: Contribution to journalArticle

319 Citations (Scopus)

Abstract

Purpose: Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed o trial to investigate this matter. Methods: We developed and conducted a placebo- controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. Results: The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed o similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P ≤ .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively). Conclusion: Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.

Original languageEnglish (US)
Pages (from-to)495-500
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number2
StatePublished - Feb 1998

Fingerprint

Hot Flashes
Vitamin E
Survivors
Breast Neoplasms
Placebos
Cross-Over Studies
Progesterone
Estrogens
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., ... Novotny, P. (1998). Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. Journal of Clinical Oncology, 16(2), 495-500.

Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. / Barton, Debra L.; Loprinzi, Charles Lawrence; Quella, Susan K.; Sloan, Jeff A; Veeder, Michael H.; Egner, James R.; Fidler, Pat; Stella, Philip J.; Swan, Debra K.; Vaught, Nancy L.; Novotny, Paul.

In: Journal of Clinical Oncology, Vol. 16, No. 2, 02.1998, p. 495-500.

Research output: Contribution to journalArticle

Barton, DL, Loprinzi, CL, Quella, SK, Sloan, JA, Veeder, MH, Egner, JR, Fidler, P, Stella, PJ, Swan, DK, Vaught, NL & Novotny, P 1998, 'Prospective evaluation of vitamin E for hot flashes in breast cancer survivors', Journal of Clinical Oncology, vol. 16, no. 2, pp. 495-500.
Barton, Debra L. ; Loprinzi, Charles Lawrence ; Quella, Susan K. ; Sloan, Jeff A ; Veeder, Michael H. ; Egner, James R. ; Fidler, Pat ; Stella, Philip J. ; Swan, Debra K. ; Vaught, Nancy L. ; Novotny, Paul. / Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 2. pp. 495-500.
@article{ea88a2000cb44859b5ad148594ac8323,
title = "Prospective evaluation of vitamin E for hot flashes in breast cancer survivors",
abstract = "Purpose: Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed o trial to investigate this matter. Methods: We developed and conducted a placebo- controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. Results: The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed o similar reduction in hot flash frequencies (25{\%} v 22{\%}; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P ≤ .05). At the study end, patients did not prefer vitamin E over the placebo (32{\%} v 29{\%}, respectively). Conclusion: Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.",
author = "Barton, {Debra L.} and Loprinzi, {Charles Lawrence} and Quella, {Susan K.} and Sloan, {Jeff A} and Veeder, {Michael H.} and Egner, {James R.} and Pat Fidler and Stella, {Philip J.} and Swan, {Debra K.} and Vaught, {Nancy L.} and Paul Novotny",
year = "1998",
month = "2",
language = "English (US)",
volume = "16",
pages = "495--500",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Prospective evaluation of vitamin E for hot flashes in breast cancer survivors

AU - Barton, Debra L.

AU - Loprinzi, Charles Lawrence

AU - Quella, Susan K.

AU - Sloan, Jeff A

AU - Veeder, Michael H.

AU - Egner, James R.

AU - Fidler, Pat

AU - Stella, Philip J.

AU - Swan, Debra K.

AU - Vaught, Nancy L.

AU - Novotny, Paul

PY - 1998/2

Y1 - 1998/2

N2 - Purpose: Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed o trial to investigate this matter. Methods: We developed and conducted a placebo- controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. Results: The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed o similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P ≤ .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively). Conclusion: Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.

AB - Purpose: Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed o trial to investigate this matter. Methods: We developed and conducted a placebo- controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. Results: The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed o similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P ≤ .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively). Conclusion: Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.

UR - http://www.scopus.com/inward/record.url?scp=0031917063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031917063&partnerID=8YFLogxK

M3 - Article

C2 - 9469333

AN - SCOPUS:0031917063

VL - 16

SP - 495

EP - 500

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -